LimmaTech raised $37m in Series A funding co-led by Adjuvant Capital, AXA IM Alts and Novo Holdings.

Health services Manufacturing Pharma

Switzerland

United States

France

Denmark

Investments

04 October 2023

Share:

LimmaTech (company)

Switzerland

Health services Manufacturing Pharma

Total investments received (USD): 40m

Round value (USD): 37m

Round investors: Adjuvant Capital AXA IM Novo A/S

Company: LimmaTech

Industry: Health services Manufacturing Pharma

Related deals

LEM Surgical raised €23.6 million series B

Health services Manufacturing Robotics

Switzerland

Investments 24 December 2023

Granite Bio raised a $30m Series A round co-led by Versant Ventures and Novartis Venture Fund

Biotech Health services Manufacturing

Switzerland

United States

Investments 24 December 2023

Vandria in a CHF18 million series A round led by ND Capital together with a small syndicate of HNW private investors.

Biotech Health services Manufacturing Pharma

Switzerland

United States

Investments 15 December 2023

Memo Therapeutics in a €26 million Series C led by Pureos Bioventures, with Swisscanto, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders

Biotech Health services Manufacturing

Switzerland

United States

United Kingdom

Luxembourg

Germany

Investments 30 October 2023

Tolremo Therapeutics raised $30m in Series A funding round led by BioMedPartners and joined by Pierre Fabre Invest.

Biotech Health services Manufacturing

Switzerland

United States

France

Investments 15 September 2023